Intranasal Drug Delivery Devices Market Size To Hit US$ 5.26 Bn By 2032

The global intranasal drug delivery devices market reached USD 1.49 billion in 2022 and is projected to hit USD 5.26 billion by 2032 with a CAGR of 13.5% from 2023 to 2032.

Crucial factors accountable for market growth are:

Increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy
High prevalence of cardiovascular diseases
Patent expiration of popular drugs, increased cases of cancer and diabetes
Growing Adoption of Self-Administration Practices
Technological advancements

Intranasal Drug Delivery Devices Market Size 2023 to 2032

Drug delivery primarily refers to a process of transporting a drug/medication into the body to have an adequate therapeutic consequence. Several methods are frequently utilized for the delivery of the medicine. Nasal and pulmonary routes are regarded to be the most prevalent types for carrying the drug. Intranasal drug delivery is a convenient delivery method for medications that are active in low dosages and display no minimum oral bioavailability such as peptides and proteins. One of the explanations for the low degree of absorption of proteins and peptides via the nasal path is quick movement distant from the absorption position in the nasal cavity owing to the Mucociliary Clearance system. The nasal path evades hepatic first pass exclusion associated with the oral transfer. The rapid inception of the therapeutic outcome is possible due to the big surface area of the nasal mucosa. This method has great potential for non-invasiveness, no first-pass absorption, and direct to the central nervous system transfer.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1253

Growth Factors:

Factors such as growing patient preference for nasal drug delivery and increasing popularity of self-administration of medications are driving the growth of intranasal drug delivery devices market. High incidence of cardiovascular disorders, increased cancer and diabetes cases, amplified focus on elderly and pediatric patients, and growing demand for home-based healthcare devices are further propelling the intranasal drug delivery devices market expansion across the globe. Additional aspects that are anticipated to fuel this industry are rapid R&D activity and reception of new drug delivery approaches and equipment’s, reformulation of injections and oral medications into the preparations to be administered by the nasal route, and quick onset of action. The simple administration and improved efficacy have amplified patient preference for the nasal drug delivery which subsequently has enhanced the demand for overall market for the nasal drug delivery devices market.

Due to the greater permeability and low enzymatic environment of the nasal cavity, and evasion of the hepatic first pass metabolism, intranasal drug delivery devices are appropriate for systemic transport of drug molecule through nose. Numerous drug delivery devices for nasal use of solid, semisolid, and liquid formulation are examined to deliver the medications to the treat most critical CNS diseases (i.e., Alzheimer’s disease, Parkinson’s disease) since it requires quick and specific aiming of medications to the brain.

Report Highlights:

Among the system segment, multi-dose systems are expected to dominate the overall market. Multi-dose systems have multiple advantages over other systems which makes them a system of choice in many settings.
The non-pressurized containers accounted for the largest revenue in the containers segment with more than 68% share in 2019. Increasing awareness regarding the use of non-pressurized containers is the major reason for high market share of non-pressurized containers. Pressurized containers are expected to grow at the topmost CAGR during the forecast time-frame.
Asthma accounted for the largest revenue in the application segment. Increasing prevalence of asthma in developing regions is the key reason for high market share of asthma.
Hospitals accounted for the largest revenue in the end-user segment. High frequency of intranasal drug delivery in hospitals is the key reason for high market share of hospitals.
Teleflex Incorporated accounted for a significant share of the global intranasal drug delivery devices market.

Table of Contents

Report Scope of the Intranasal Drug Delivery Devices Market:

Report Highlights	Details
Market Size by 2032	US$ 5.26 Billion
Growth Rate from 2023 to 2032	CAGR of 13.5%
Base Year	2022
Forecast Period	2023 to 2032

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 37%. U.S. represented the highest share in the North American region primarily due to presence of leading market players and high awareness regarding alternate drug delivery mechanisms. Furthermore, early adoption of latest healthcare technologies also contributed to the high market share of the United States.

Europe was the second important market chiefly due to presence of latest healthcare infrastructure and high investment in research and development. The presence of skilled researchers in the European region is also expected to boost the demand for Intranasal Drug Delivery Devices market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around 14% in the forecast period due to high incidence of cancer. Latin America and the African and Middle Eastern region will display noticeable growth.

High investment in the research and development along with acquisition, mergers, and collaborations are the key strategies undertaken by companies operating in the global Intranasal Drug Delivery Devices market. Recently, scientists have evolved an inhalation delivery arrangement for vaccines that produces effective immune responses in non-human primates, without triggering lung damage. This innovation can lead to novel therapeutics for respirational diseases like the corona virus Covid-19.